


What is claimed is:

1. A process for treating a cytodegenerative disease comprising administering to a subject in need thereof a compound having cytoprotective activity comprising a hydroxy-substituted aromatic ring structure and a non-fused polycyclic, hydrophobic substituent attached thereto.


2. The process of claim 1 wherein the compound has the formula:



wherein n is 1 or 2, R<sup>1</sup> is a non-fused polycyclic substituent, and R<sup>2</sup> and R<sup>3</sup> are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted hydrocarbyl.

3. The process of claim 2 wherein R<sup>2</sup> and R<sup>3</sup> are bound to different carbon atoms, and further wherein R<sup>2</sup> and R<sup>3</sup> and the carbon atoms to which they are attached form a fused ring.

4. The process of claim 3 wherein said compound has the formula:




wherein:  $R^1$  and  $R^x$  are independently selected from the group consisting of a non-fused, polycyclic hydrophobic substituent, hydrogen, and substituted or unsubstituted alkyl, with the proviso that at least one of  $R^1$  and  $R^x$  is a non-fused, polycyclic hydrophobic substituent;  $R^{13}$  is hydrogen or substituted or unsubstituted alkyl; and,  $R^z$  is hydrogen, hydroxy, substituted or unsubstituted alkyl, or oxo.


5. The process of claim 4 wherein said non-fused polycyclic, hydrophobic substituent is adamantyl.

6. The process of claim 5 wherein  $R^z$  is oxo.

7. The process of claim 6 wherein said compound has the formula:



or




and wherein  $R^x$  are as defined in claim 4.


1000450 110501  
105011 0542001

8. The process of claim 7 wherein  $R^*$  is hydrogen or methyl.


9. The process of claim 8 wherein the compound has the formula:




10. The process of claim 8 wherein the compound has the formula:



11. The process of claim 4 wherein said compound has the formula:




or




wherein R<sup>1</sup> and R<sup>x</sup> are as defined in claim 4.

12. The process of claim 11 wherein R<sup>1</sup> is adamantyl and R<sup>x</sup> is hydrogen, methyl or methylpropyl.

13. The process of claim 12 wherein the compound has the formula:




14. The process of claim 12 wherein the compound has the formula:



1000450 10504

15. The process of claim 12 wherein the compound has the formula:



16. The process of claim 1 wherein the non-fused polycyclic, hydrophobic substituent is bicyclic.

17. The process of claim 16 wherein said substituent is selected from the group consisting of bicyclo[2.2.1]heptanyl and bicyclo[3.2.1]octanyl.

18. The process of claim 1 wherein the nonfused polycyclic, hydrophobic substituent is tricyclic.

19. The process of claim 18 wherein said substituent is adamantyl.

20. The process of claim 1 wherein the hydroxy-substituted, aromatic ring structure is polycyclic.

21. The process of claim 20 wherein the polycyclic ring structure is steroidal.

22. The process of claim 21 wherein the steroidal structure is phenolic.

23. The process of claim 22 wherein said polycyclic phenol is selected from the group consisting of estradiol, estratrienol and estrone.

FOGOT 0542000F

24. The process of claim 23 wherein said polycyclic phenol is an estrone.

25. The process of claim 24, wherein said estrone is selected from 2-(1-adamantyl)-3-hydroxyestra-1,3,5(10)-trien-17-one, and 2-(1-adamantyl)-3-hydroxy-4-methylestra-1,3,5(10)-trien-17-one.

26. The process of claim 23 wherein said polycyclic phenol is an estradiol.

27. The process of claim 26 wherein said estradiol is selected from the group consisting of (17 $\beta$ )-2-(1-adamantyl)-estra-1,3,5(10)-triene-3,17-diol, (17 $\alpha$ )-2-(1-adamantyl)-estra-1,3,5(10)-triene-3,17-diol, (17 $\beta$ )-2-(1-adamantyl)-4-(1-methylpropyl)estra-1,3,5(10)-triene-3,17-diol, (17 $\alpha$ )-2-(1-adamantyl)-4-(1-methylpropyl)estra-1,3,5(10)-triene-3,17-diol, or an enantiomer thereof.

28. The process of claim 21 wherein the steroidal structure is catecholic.

29. The process of claim 28 wherein said polycyclic catechol is selected from the group consisting of 2-hydroxy-(17 $\beta$ )-estradiol, 2-hydroxy-(17 $\alpha$ )-estradiol, or an enantiomer thereof.

30. The process of claim 1 comprising administering a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier, excipient or diluent.

31. The process of claim 1 wherein said subject is an animal.

32. The process of claim 1 wherein said subject is a human.


1000450 110501

33. A process for conferring cytoprotection on a population of cells, the process comprising administering to the population of cells a compound having cytoprotective activity comprising a hydroxy-substituted aromatic ring structure and a non-fused polycyclic, hydrophobic substituent attached thereto.


34. The process of claim 33 comprising administering a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier, excipient or diluent.

35. The process of claim 34 wherein said cells are neurons.

36. A compound having cytoprotective activity, the compound having the formula:




wherein:  $n$  is 1 or 2;  $R^1$  is a non-fused polycyclic, hydrophobic substituent;  $R^x$  is selected from the group consisting of hydrogen and substituted or unsubstituted alkyl;  $R^{13}$  is hydrogen or substituted or unsubstituted alkyl; and,  $R^z$  is hydrogen, hydroxy, substituted or unsubstituted alkyl, or oxo, with the proviso that when the compound has the following structure:




10 Rx is not hydrogen.

37. The compound of claim 36 wherein said compound has the formula:



or




wherein R<sup>1</sup> and R<sup>x</sup> are as defined in claim 36.

38. The compound of claim 36 wherein R<sup>1</sup> is adamantyl and R<sup>x</sup> is hydrogen or methyl.

1000449 10001




39. The compound of claim 38 wherein the compound has the formula:




or the enantiomer thereof.

40. The compound of claim 38 wherein the compound has the formula:




or the enantiomer thereof.

41. The compound of claim 36 wherein said compound has the formula:



10007450-10501


or



wherein R<sup>1</sup> and R<sup>x</sup> are as defined in claim 36.

42. The compound of claim 41 wherein R<sup>1</sup> is adamantyl and R<sup>x</sup> is hydrogen, methyl or methylpropyl.


43. The compound of claim 42 wherein the compound has the formula:



or the enantiomer thereof.


10007430-10501  
T05077-0542001

44. The compound of claim 42 wherein the compound has the formula:




or the enantiomer thereof.

45. The process of claim 42 wherein the compound has the formula:



or the enantiomer thereof.

46. A compound having cytoprotective activity, the compound having the formula:



wherein:

the compound optionally has one or more unsaturated  
5 bonds in conjugation with the aromatic A-ring between C-6  
and C-7, C-8 and C-9 or C-9 and C-11, with the proviso that  
when C-8 or C-9 is unsaturated, R<sup>y</sup> is not bound thereto;

n ranges from 1 to 3;

R<sup>1</sup> is a non-fused polycyclic, hydrophobic substituent;

10 R<sup>x</sup> is selected from the group consisting of hydrogen and  
substituted or unsubstituted alkyl;

R<sup>y</sup> and R<sup>v</sup> are independently selected from hydrogen,  
substituted or unsubstituted alkyl, halo, amido, sulfate,  
and nitrate;


15 p and q range from 1 to 3;

R<sup>13</sup> is hydrogen or substituted or unsubstituted  
hydrocarbyl, halo, amido, sulfate or nitrate;

R<sup>z</sup> is hydrogen, hydroxy, substituted or unsubstituted  
alkyl, or oxo; and,

20 t ranges from 1 to 3;

with the proviso that when the compound has the  
following structure:



R<sup>x</sup> is not hydrogen.

47. The compound of claim 46 wherein R<sup>1</sup> is adamantyl.

48. The compound of claim 47 wherein a single R<sup>z</sup>  
substituent is present on the D-ring at the C-17 position.

49. The compound of claim 48 wherein R<sup>z</sup> is oxo, or  
alpha or beta hydroxy.

50. The compound of claim 49 wherein  $R^x$  and  $R^{13}$  are methyl.

51. The compound of claim 50 wherein the configurations at C-8, C-9, C-13 and C-14 are alpha, beta, alpha, and beta, respectively.

10007450 10504  
10504 0542000F